Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NADK | O95544 | 2/20 | 0.61 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.60 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672193 | 1.00 | NADK (0.61) | NADKHSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL30237237 | 1.00 | NADK (0.61) | NADKHSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL28537245 | 0.92 | NADK (0.59) | NADKHSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL12360838 | 0.91 | NADK (0.60) | NADKHSPA5HSPA8RXFP1 | |
| SCHEMBL12376381 | 0.91 | NADK (0.60) | NADKHSPA5HSPA8RXFP1 | |
| SCHEMBL23548003 | 0.89 | HSPA8 (0.62) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL1737260 | 0.89 | HSPA8 (0.76) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL28087475 | 0.89 | HSPA8 (0.62) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL6388256 | 0.89 | HSPA8 (0.62) | HSPA5HSPA8RXFP1HSD17B10GAPDH | |
| SCHEMBL30484790 | 0.88 | HSPA8 (0.61) | HSPA5HSPA8RXFP1HSD17B10GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-9487553-B2 | Boranophosphate analogues of cyclic nucleotides | BIOLOG LIFE SCIENCE INSTITUTE FORSCHUNGSLABOR UND BIOCHEMICA-VERTRIEB GMBH (DE) | 2016-11-08 | — | — | US | disclosed |
| EP-2691403-B1 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES | BIOLOG LIFE SCIENCE INST FORSCHUNGSLABOR UND BIOCHEMICA VERTRIEB GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| EP-1511757-B1 | NEW COMPOUNDS FOR MODULATING THE ACTIVITY OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | UNIV MEDISCH CENTRUM UTRECHT (NL) | 2015-11-04 | — | — | EP | disclosed |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140088033-A1 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES | BIOLOG LIFE SCIENCE INSTITUTE FORSCHUNGSLABOR UND BIOCHEMICA-VERTRIEB GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003104250-A1 | NEW COMPOUNDS FOR MODULATING THE ACTIVITY OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | KYLIX, B. V. (NL) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | NADK 236/4885HSPA5 2092/4885HSPA8 1928/4885 |
| US-20140088033-A1 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES | NT5C2, NT5E, ENPP3 | NADK 760/4885HSPA5 1639/4885HSPA8 2358/4885 |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | NADK 228/4885HSPA5 2044/4885HSPA8 3951/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | NADK 227/4885HSPA5 1811/4885HSPA8 3709/4885 |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | NADK 203/4885HSPA5 1435/4885HSPA8 2731/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | NADK 2688/4885HSPA5 2282/4885HSPA8 2789/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | NADK 228/4885HSPA5 2044/4885HSPA8 3951/4885 |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | NADK 228/4885HSPA5 2044/4885HSPA8 3951/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | NADK 228/4885HSPA5 2044/4885HSPA8 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.